Shire Acquisition Inc. — Investor Relations & Filings

Shire Acquisition Inc. was a corporate entity associated with Shire plc, a global biotechnology company specializing in the development and commercialization of treatments for rare diseases and highly specialized conditions. Shire's core business focused on innovative biopharmaceuticals, particularly orphan drugs, targeting patient populations with limited treatment options across therapeutic areas including hematology, immunology, neuroscience, and gastrointestinal disorders. Shire plc was acquired by Takeda Pharmaceuticals in January 2019 for $62 billion, marking one of the largest acquisitions in the pharmaceutical industry. Following the transaction, Shire's operations and assets were integrated into Takeda's global structure, significantly expanding Takeda's portfolio in specialized medicine and rare diseases.